{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:21:24Z","timestamp":1784582484423,"version":"3.55.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100008963","name":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04240-9","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:17:44Z","timestamp":1773749864000},"page":"2056-2067","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SEOM\u2013TTCC clinical guidelines for the treatment of head and neck cancer (2025)"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1431-2780","authenticated-orcid":false,"given":"Virginia","family":"Arrazubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"P\u00e9rez Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rubi\u00f3-Casadevall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Bruixola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Carral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Castelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Cirauqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"4240_CR1","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","volume":"29","author":"AK Chaturvedi","year":"2011","unstructured":"Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294\u2013301. https:\/\/doi.org\/10.1200\/JCO.2011.36.4596.","journal-title":"J Clin Oncol"},{"key":"4240_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMOA0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-T\u00e2n PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24\u201335. https:\/\/doi.org\/10.1056\/NEJMOA0912217.","journal-title":"N Engl J Med"},{"key":"4240_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-020-70118-7","volume":"10","author":"M Mena","year":"2020","unstructured":"Mena M, Frias-Gomez J, Taberna M, Quir\u00f3s B, Marquez S, Clavero O, et al. Epidemiology of human papillomavirus-related oropharyngeal cancer in a classically low-burden region of southern Europe. Sci Rep. 2020;10:13219. https:\/\/doi.org\/10.1038\/S41598-020-70118-7.","journal-title":"Sci Rep"},{"key":"4240_CR4","unstructured":"Estimaciones de la incidencia del c\u00e1ncer en Espa\u00f1a, 2024. Red Espa\u00f1ola de Registros de C\u00e1ncer (REDECAN), 2024 [Internet]. [cited 2024 Oct 20]. https:\/\/redecan.org\/storage\/documents\/031b5800-a7fe-4c2b-8a09-a38d046365df.pdf. Accessed 20 Oct 2024"},{"key":"4240_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/IJERPH19084802","author":"J Rubi\u00f3-Casadevall","year":"2022","unstructured":"Rubi\u00f3-Casadevall J, Ciurana E, Puigdemont M, Sanvisens A, Marruecos J, Mir\u00f3 J, et al. Population-based analysis of trends in incidence and survival of human papilloma virus-related oropharyngeal cancer in a low-burden region of Southern Europe. Int J Environ Res Public Health. 2022. https:\/\/doi.org\/10.3390\/IJERPH19084802.","journal-title":"Int J Environ Res Public Health"},{"key":"4240_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/CAAC.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/CAAC.21834.","journal-title":"CA Cancer J Clin"},{"key":"4240_CR7","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","volume":"18","author":"G Gatta","year":"2017","unstructured":"Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 2017;18:1022\u201339. https:\/\/doi.org\/10.1016\/S1470-2045(17)30445-X.","journal-title":"Lancet Oncol"},{"key":"4240_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1086\/656735","volume":"51","author":"AR Khan","year":"2010","unstructured":"Khan AR, Khan S, Zimmerman V, Baddour LM, Tleyjeh IM. Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines. Clin Infect Dis. 2010;51:1147\u201356. https:\/\/doi.org\/10.1086\/656735.","journal-title":"Clin Infect Dis"},{"key":"4240_CR9","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1056\/NEJMOA1514493","volume":"374","author":"H Mehanna","year":"2016","unstructured":"Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M, Hartley AGJ, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med. 2016;374:1444\u201354. https:\/\/doi.org\/10.1056\/NEJMOA1514493.","journal-title":"N Engl J Med"},{"key":"4240_CR10","first-page":"57","volume-title":"TNM Classification of Malignant Tumors International Union Against Cancer","author":"J Brierley","year":"2017","unstructured":"Brierley J, Gospodarowicz MD, Wittekind CT. TNM Classification of Malignant Tumors International Union Against Cancer. 8th ed. Oxford England: Wiley; 2017. p. 57\u201362.","edition":"8"},{"key":"4240_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1177\/0194599817746909","volume":"158","author":"MA Ellis","year":"2018","unstructured":"Ellis MA, Graboyes EM, Wahlquist AE, Neskey DM, Kaczmar JM, Schopper HK, et al. Primary surgery vs radiotherapy for early stage oral cavity cancer. Otolaryngol Head Neck Surg. 2018;158:649\u201359. https:\/\/doi.org\/10.1177\/0194599817746909.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"4240_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/J.IJOM.2023.08.004","volume":"53","author":"EA Al-Moraissi","year":"2024","unstructured":"Al-Moraissi EA, Alkhutari AS, de Bree R, Kaur A, Al-Tairi NH, P\u00e9rez-Say\u00e1ns M. Management of clinically node-negative early-stage oral cancer: network meta-analysis of randomized clinical trials. Int J Oral Maxillofac Surg. 2024;53:179\u201390. https:\/\/doi.org\/10.1016\/J.IJOM.2023.08.004.","journal-title":"Int J Oral Maxillofac Surg"},{"key":"4240_CR13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/J.IJROBP.2012.08.033","volume":"85","author":"EJ Moore","year":"2013","unstructured":"Moore EJ, Hinni ML. Critical review: transoral laser microsurgery and robotic-assisted surgery for oropharynx cancer including human papillomavirus-related cancer. Int J Radiat Oncol Biol Phys. 2013;85:1163\u20137. https:\/\/doi.org\/10.1016\/J.IJROBP.2012.08.033.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4240_CR14","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S1470-2045(19)30410-3","volume":"20","author":"AC Nichols","year":"2019","unstructured":"Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol. 2019;20:1349\u201359. https:\/\/doi.org\/10.1016\/S1470-2045(19)30410-3.","journal-title":"Lancet Oncol"},{"key":"4240_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/J.JCMS.2023.12.012","volume":"52","author":"EA Al-Moraissi","year":"2024","unstructured":"Al-Moraissi EA, Marwan H, Elayah SA, Traxler-Weidenauer D, Paraskevopoulos K, Amir Rais M, et al. Sentinel lymph node biopsy versus elective neck dissection in management of the clinically negative (cN0) neck in patients with oral squamous cell carcinoma: a systematic review and meta-analysis. J Craniomaxillofac Surg. 2024;52:141\u201350. https:\/\/doi.org\/10.1016\/J.JCMS.2023.12.012.","journal-title":"J Craniomaxillofac Surg"},{"key":"4240_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/J.IJROBP.2023.04.035","volume":"117","author":"NB Razavian","year":"2023","unstructured":"Razavian NB, D\u2019Agostino RB, Shenker RF, Hughes RT. Intensity-modulated radiation therapy for early-stage squamous cell carcinoma of the glottic larynx: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2023;117:652\u201363. https:\/\/doi.org\/10.1016\/J.IJROBP.2023.04.035.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4240_CR17","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/HED.27325","volume":"45","author":"MR Papazian","year":"2023","unstructured":"Papazian MR, Chow MS, Jacobson AS, Tran T, Persky MS, Persky MJ. Role of transoral robotic surgery in surgical treatment of early-stage supraglottic larynx carcinoma. Head Neck. 2023;45:972\u201382. https:\/\/doi.org\/10.1002\/HED.27325.","journal-title":"Head Neck"},{"key":"4240_CR18","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/HED.23945","volume":"38","author":"LJ Liao","year":"2016","unstructured":"Liao LJ, Hsu WL, Wang CT, Lo WC, Lai MS. Analysis of sentinel node biopsy combined with other diagnostic tools in staging cN0 head and neck cancer: a diagnostic meta-analysis. Head Neck. 2016;38:628\u201334. https:\/\/doi.org\/10.1002\/HED.23945.","journal-title":"Head Neck"},{"key":"4240_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1056\/NEJMoa1506007","volume":"373","author":"AK D\u2019Cruz","year":"2015","unstructured":"D\u2019Cruz AK, Vaish R, Kapre N, Dandekar M, Gupta S, Hawaldar R, et al. Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer. N Engl J Med. 2015;373:521\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1506007.","journal-title":"N Engl J Med"},{"key":"4240_CR20","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/ARCHOTOL.134.5.536","volume":"134","author":"KT Robbins","year":"2008","unstructured":"Robbins KT, Shaha AR, Medina JE, Califano JA, Wolf GT, Ferlito A, et al. Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg. 2008;134:536\u20138. https:\/\/doi.org\/10.1001\/ARCHOTOL.134.5.536.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"4240_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1470-2045(10)70290-4","volume":"12","author":"CM Nutting","year":"2011","unstructured":"Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12:127\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(10)70290-4.","journal-title":"Lancet Oncol"},{"key":"4240_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1634\/THEONCOLOGIST.10-3-215","volume":"10","author":"J Bernier","year":"2005","unstructured":"Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? Oncologist. 2005;10:215\u201324. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.10-3-215.","journal-title":"Oncologist"},{"key":"4240_CR23","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1200\/JCO.21.01293","volume":"40","author":"N Kiyota","year":"2022","unstructured":"Kiyota N, Tahara M, Mizusawa J, Kodaira T, Fujii H, Yamazaki T, et al. Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II\/III randomized controlled trial. J Clin Oncol. 2022;40:1980\u201390. https:\/\/doi.org\/10.1200\/JCO.21.01293.","journal-title":"J Clin Oncol"},{"key":"4240_CR24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_SUPPL.LBA2","author":"J Bourhis","year":"2025","unstructured":"Bourhis J, Aup\u00e9rin A, Borel C, Lefebvre G, Racadot S, Geoffrois L, Sun XS, Saada E, Cirauqui B,\nRutkowski T, Henry S, Modesto A, Johnson A, Chapet S, Calderon B, Sire C, Malard O, Bainaud M, Da Silva Motta A, Thureau S, Pointreau Y,\nBlanchard P, Buiret G, Bozec L, Lopez S, Vanbockstael J, Bosset M, Greilsamer C, Daste A, Bruna A, N'Guyen F, Plana M, Iruarrizaga E, Temam S,\nEven C, Ruiz EP, Bert M, Karamouza E, Thariat J, Kazmierska J, Psyrri A, Mesia R, Tao Y. Nivolumab added to cisplatin and radiotherapy versus\ncisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC\n2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial. Lancet. 2026 Jan 24;407(10526):363-374. https:\/\/doi.org\/10.1016\/S0140-6736(25)01850-1.\nEpub 2025 Dec 22. PMID: 41448222.","journal-title":"J Clin Oncol."},{"key":"4240_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01829","author":"M Machtay","year":"2025","unstructured":"Machtay M, Torres-Saavedra PA, Thorstad W, Nguyen-T\u00e2n PF, Siu LL, Holsinger FC, et al. <article-title update=\"added\">Postoperative radiotherapy \u00b1 cetuximab for intermediate-risk head and neck cancer. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO-24-01829.","journal-title":"J Clin Oncol"},{"key":"4240_CR26","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/ANNONC\/MDT555","volume":"25","author":"P Bossi","year":"2014","unstructured":"Bossi P, Lo Vullo S, Guzzo M, Mariani L, Granata R, Orlandi E, et al. Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. Ann Oncol. 2014;25:462\u20136. https:\/\/doi.org\/10.1093\/ANNONC\/MDT555.","journal-title":"Ann Oncol"},{"key":"4240_CR27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2415434","author":"R Uppaluri","year":"2025","unstructured":"Uppaluri R, Haddad RI, Tao Y, Le Tourneau C, Lee NY, Westra W, et al. Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMOA2415434.","journal-title":"N Engl J Med"},{"key":"4240_CR28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/J.RADONC.2021.01.013","volume":"156","author":"B Lacas","year":"2021","unstructured":"Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021;156:281\u201393. https:\/\/doi.org\/10.1016\/J.RADONC.2021.01.013.","journal-title":"Radiother Oncol"},{"key":"4240_CR29","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1634\/THEONCOLOGIST.2017-0015","volume":"22","author":"P Szturz","year":"2017","unstructured":"Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, et al. Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data. Oncologist. 2017;22:1056\u201366. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2017-0015.","journal-title":"Oncologist"},{"key":"4240_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","volume":"11","author":"JA Bonner","year":"2010","unstructured":"Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(09)70311-0.","journal-title":"Lancet Oncol"},{"key":"4240_CR31","doi-asserted-by":"publisher","first-page":"S556","DOI":"10.1016\/j.annonc.2023.09.2003","volume":"34","author":"P Blanchard","year":"2023","unstructured":"Blanchard P, Cheugoua-Zanetsie M, Deneche I, Rosenthal DI, Gillison M, Eriksen JG, et al. 857O MACH-EGFR: individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN). Ann Oncol. 2023;34:S556. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2003.","journal-title":"Ann Oncol"},{"key":"4240_CR32","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","volume":"25","author":"JP Machiels","year":"2024","unstructured":"Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, et al. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2024;25:572\u201387. https:\/\/doi.org\/10.1016\/S1470-2045(24)00100-1.","journal-title":"Lancet Oncol"},{"key":"4240_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","volume":"22","author":"NY Lee","year":"2021","unstructured":"Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22:450\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(20)30737-3.","journal-title":"Lancet Oncol"},{"key":"4240_CR34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1470-2045(21)00076-0","volume":"22","author":"C Petit","year":"2021","unstructured":"Petit C, Lacas B, Pignon JP, Le QT, Gr\u00e9goire V, Grau C, et al. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncol. 2021;22:727\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(21)00076-0.","journal-title":"Lancet Oncol"},{"key":"4240_CR35","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMOA071028","volume":"357","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695\u2013704. https:\/\/doi.org\/10.1056\/NEJMOA071028.","journal-title":"N Engl J Med"},{"key":"4240_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/J.ORALONCOLOGY.2022.106087","author":"R Hitt","year":"2022","unstructured":"Hitt R, Mes\u00eda R, Lozano A, Iglesias Docampo L, Grau JJ, Taberna M, et al. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer. Oral Oncol. 2022. https:\/\/doi.org\/10.1016\/J.ORALONCOLOGY.2022.106087.","journal-title":"Oral Oncol"},{"key":"4240_CR37","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1200\/JCO.2015.61.2978","volume":"33","author":"AA Forastiere","year":"2015","unstructured":"Forastiere AA, Weber RS, Trotti A. Organ preservation for advanced larynx cancer: issues and outcomes. J Clin Oncol. 2015;33:3262\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.61.2978.","journal-title":"J Clin Oncol"},{"key":"4240_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2023.104105","volume":"45","author":"T M\u00fcderris","year":"2024","unstructured":"M\u00fcderris T, Sevil E, G\u00fcl F. Transoral robotic supraglottic laryngectomy: long-term functional and oncologic outcomes. Am J Otolaryngol. 2024;45:104105. https:\/\/doi.org\/10.1016\/j.amjoto.2023.104105.","journal-title":"Am J Otolaryngol"},{"key":"4240_CR39","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1200\/JCO.2012.42.3988","volume":"31","author":"JL Lefebvre","year":"2013","unstructured":"Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013;31:853\u20139. https:\/\/doi.org\/10.1200\/JCO.2012.42.3988.","journal-title":"J Clin Oncol"},{"key":"4240_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(23)00013-X","volume":"24","author":"H Mehanna","year":"2023","unstructured":"Mehanna H, Taberna M, von Buchwald C, Tous S, Brooks J, Mena M, et al. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis. Lancet Oncol. 2023;24:239\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(23)00013-X.","journal-title":"Lancet Oncol"},{"key":"4240_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","volume":"393","author":"ML Gillison","year":"2019","unstructured":"Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393:40\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(18)32779-X.","journal-title":"Lancet"},{"key":"4240_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","volume":"393","author":"H Mehanna","year":"2019","unstructured":"Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393:51\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(18)32752-1.","journal-title":"Lancet"},{"key":"4240_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/J.RADONC.2023.109686","author":"P Lin","year":"2023","unstructured":"Lin P, Holloway L, Min M, Lee M, Fowler A. Prognostic and predictive values of baseline and mid-treatment FDG-PET in oropharyngeal carcinoma treated with primary definitive (chemo)radiation and impact of HPV status: review of current literature and emerging roles. Radiother Oncol. 2023. https:\/\/doi.org\/10.1016\/J.RADONC.2023.109686.","journal-title":"Radiother Oncol"},{"key":"4240_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS14163894","volume":"14","author":"H Bahig","year":"2022","unstructured":"Bahig H, Huang SH, O\u2019Sullivan B. Oligometastatic head and neck cancer: challenges and perspectives. Cancers (Basel). 2022;14:3894. https:\/\/doi.org\/10.3390\/CANCERS14163894.","journal-title":"Cancers (Basel)"},{"key":"4240_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS16112103","author":"E Deuss","year":"2024","unstructured":"Deuss E, K\u00fcrten C, Fehr L, Kahl L, Zimmer S, K\u00fcnzel J, et al. Standardized digital image analysis of PD-L1 expression in head and neck squamous cell carcinoma reveals intra- and inter-sample heterogeneity with therapeutic implications. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/CANCERS16112103.","journal-title":"Cancers (Basel)"},{"key":"4240_CR46","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7.","journal-title":"Lancet"},{"key":"4240_CR47","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMOA0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116\u201327. https:\/\/doi.org\/10.1056\/NEJMOA0802656.","journal-title":"N Engl J Med"},{"key":"4240_CR48","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S1470-2045(20)30755-5","volume":"22","author":"J Guigay","year":"2021","unstructured":"Guigay J, Aup\u00e9rin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22:463\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(20)30755-5.","journal-title":"Lancet Oncol"},{"key":"4240_CR49","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/ANNONC\/MDR367","volume":"23","author":"R Hitt","year":"2012","unstructured":"Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, Garc\u00eda-S\u00e1enz JA, Cruz-Hernandez JJ. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and\/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23:1016\u201322. https:\/\/doi.org\/10.1093\/ANNONC\/MDR367.","journal-title":"Ann Oncol"},{"key":"4240_CR50","doi-asserted-by":"publisher","first-page":"1226939","DOI":"10.3389\/FONC.2023.1226939\/BIBTEX","volume":"13","author":"J Rubi\u00f3-Casadevall","year":"2023","unstructured":"Rubi\u00f3-Casadevall J, CirauquiCirauqui B, Martinez Trufero J, Plana Serrahima M, Garc\u00edaCasta\u00f1o A, CarralMaseda A, et al. TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck. Front Oncol. 2023;13:1226939. https:\/\/doi.org\/10.3389\/FONC.2023.1226939\/BIBTEX.","journal-title":"Front Oncol"},{"key":"4240_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2023.1160144","author":"CM Black","year":"2023","unstructured":"Black CM, Hanna GJ, Wang L, Ramakrishnan K, Goto D, Turzhitsky V, et al. Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent\/metastatic head and neck squamous cell carcinoma. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/FONC.2023.1160144.","journal-title":"Front Oncol."},{"key":"4240_CR52","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1602252.","journal-title":"N Engl J Med"},{"key":"4240_CR53","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393:156\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(18)31999-8.","journal-title":"Lancet"},{"key":"4240_CR54","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.21873\/ANTICANRES.16320","volume":"43","author":"L Macia-Rivas","year":"2023","unstructured":"Macia-Rivas L, Fernandez-Laguna CL, Alvarez-Asteinza C, Maray I, Carbajales-Alvarez M, Lozano-Blazquez A. Real-world data study of the efficacy and toxicity of Nivolumab vs. Cetuximab and predictors of response to Nivolumab in recurrent\/metastatic squamous cell carcinoma of the head and neck in a European population. Anticancer Res. 2023;43:1681\u20138. https:\/\/doi.org\/10.21873\/ANTICANRES.16320.","journal-title":"Anticancer Res"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04240-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04240-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04240-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:32:27Z","timestamp":1779204747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04240-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":54,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4240"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04240-9","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Virginia Arrazubi reports Advisory Board, and Speaker from BMS and MSD and Speaker from Beigene, Lilly, Astellas and Organon. Marc Oliva reports Advisory Board, and Speaker from Merck; Other from Transgene and Guardant Health; personal fees from Obatica; Grant from Roche and Speaker from BMS. Pedro P\u00e9rez reports Speaker, and personal fees, non-financial support from MSD and Merck, and Speaker, Grant, personal fees, non-financial support from BMS. Jordi Rubi\u00f3-Casadevall reports Advisory Board from Novartis, Sanofi, Merck and Lilly, and Speaker from IPSEN. Gemma Bruixola reports Speaker from Merck, BMS and MSD. Beatriz Cirauqui reports Advisory Board, Speaker, Grant from Merck, BMS and MSD, and Speaker from Pfizer. Antonio Rueda Dom\u00ednguez reports Advisory Board, and Speaker from Roche, Takeda, Gilead and Merck; Speaker from MSD and BMS. Lara Iglesias, Alberto Carral and Beatriz Castelo have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}